Ultragenyx Pharmaceutical Inc.
Here’s whether Ultragenyx Pharmaceutical Inc. (RARE) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+2.58% over 10 days); RSI 55 — healthy momentum range; 3-month momentum positive (+10.4%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); weak 1-year return of -12.5%. Currently 35.2% off its 52-week high. Score: -1/7.
RARE is trading below its 200-day MA ($26.42) — a key warning sign the longer-term trend is under pressure. An RSI of 55.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -12.5% compares to +20.5% for SPY (trailed the market by 33.0%). The current 35.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.